checkAd

     325  0 Kommentare Theravance Biopharma Receives FDA Fast Track Designation for TD-8954 for Use With Enteral Feeding in Critically Ill Patients - Seite 3

    Contact Information:

    Renee Gala
    Chief Financial Officer
    650-808-4045
    investor.relations@theravance.com

    Tim Brons
    Vida Strategic Partners (media)
    646-319-8981
    tbrons@vidasp.com

    Lesen Sie auch


    Seite 3 von 3

    Verfasst von Marketwired
    3 im Artikel enthaltene WerteIm Artikel enthaltene Werte
    Theravance Biopharma Receives FDA Fast Track Designation for TD-8954 for Use With Enteral Feeding in Critically Ill Patients - Seite 3 DUBLIN, IRELAND--(Marketwired - Aug 6, 2015) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to TD-8954 for …